Help protect your patients with T2D and established CVD

INVOKANA® is the only T2D pill approved to reduce the risk of heart attack, stroke, and cardiovascular death1

  • As demonstrated in 6656 patients in the longest landmark cardiovascular outcomes program for an oral type 2 diabetes therapy1-3

Early (26 weeks) and sustained results1*

  • The primary endpoint of the CANVAS Program (N=10,142) was 3-point MACE (heart attack, stroke, and CV death) for patients with T2D and established CVD or ≥2 risk factors for CVD2: HR=0.86 (95% CI: 0.75, 0.97); P=0.02 for superiority
  • Cardiovascular outcomes trials for type 2 diabetes agents are powered to evaluate 3-point MACE5

*These results reflect the subgroup of patients from the CANVAS Program with established cardiovascular disease.

 

All 3 components positively contributed to the primary endpoint1*

CV=cardiovascular; CVD=cardiovascular disease; HR=hazard ratio; MACE=major adverse cardiovascular events; RRR=relative risk reduction; T2D=type 2 diabetes.

 

Use of background therapy for glycemic management and other control of risk factors was guided by best practice according to local guidelines.

Select baseline background therapies in patients with established CVD1

 
Cardioprotective agents
Statin 81.1%
Antithrombotic 86.6%
RAAS inhibitor (ACEi/ARB) 79.8%
Beta blocker 64.2%
Diuretic 44.2%
Calcium channel blocker 33.9%
Antihyperglycemic agents
Insulin 51.3%
Sulfonylurea 41.0%
Metformin 74.4%
GLP1 receptor agonist 3.7%
DPP4 inhibitor 11.5%

ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; CVD=cardiovascular disease; DPP4=dipeptidyl peptidase-4; GLP1=glucagon-like peptide-1; MACE=major adverse cardiovascular events; MI=myocardial infarction; RAAS=renin-angiotensin-aldosterone system.

Select baseline characteristics1

 
Profile
Age 63.6 years
Duration of diabetes 13.2 years
A1C 8.2%
eGFR 75.5 mL/min/1.73 m2
BMI 31.8 kg/m2
Current smoker 14.1%
LDL cholesterol 85.1 mg/dL
Symptomatic atherosclerotic cardiovascular events
MI 44.1%
Stroke 19.2%
Hospitalization for unstable angina 10.9%
Coronary revascularization 53.5%
Carotid revascularization 1.2%
Peripheral revascularization 7.8%
Amputation 3.3%
Peripheral vascular disease2 20.8%
Other comorbid conditions
Retinopathy 21.8%
Nephropathy 16.9%
Neuropathy 32.0%
Hypertension 89.3%
Heart failure 17.6%

CVD=cardiovascular disease; MI=myocardial infarction.

Cardioprotective benefits are defined as protection against MACE, including nonfatal MI, nonfatal stroke, and cardiovascular death.

 

Long-term cardiovascular outcomes trial at 338 weeks (Mahaffey et al)

The CANVAS Program was a double-blind comparison of the effects of INVOKANA® vs placebo from an integrated analysis of 2 large-scale trials (the CANVAS trial and the CANVAS-R trial) including 10,142 men and women with type 2 diabetes who were either ≥30 years of age with a history of symptomatic atherosclerotic cardiovascular events or ≥50 years of age with ≥2 risk factors for cardiovascular disease. The established CVD subgroup included ~65% of all patients. The primary efficacy outcome for these analyses was the composite of cardiovascular mortality, nonfatal MI, or nonfatal stroke.1

References: 1. Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323-334. 2. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med. 2017;377(7):644-657. 3. Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. doi:10.1161/CIRCULATIONAHA.118.034222. 4. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. 5. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US Food and Drug Administration Web site. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Updated December 2008. Accessed October 30, 2018.